BPTH (Bio-Path Holdings) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


What is Bio-Path Holdings Tariff Resilience Score?

Bio-Path Holdings BPTH +2.46% Tariff Resilience Score is 6 as of Jun. 29, 2026. The stock has 1 warning sign investors should review. Among 1,375 Biotechnology companies, Bio-Path Holdings ranks better than 76% on this metric.

Bio-Path Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Bio-Path Holdings has As a biotech firm, BPTH may face some supply chain risks for raw materials, but its primary market is domestic. The impact of tariffs is moderate, with potential mitigation through alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bio-Path Holdings might have Average Resilient.

Bio-Path Holdings  (OTCPK:BPTH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bio-Path Holdings Tariff Resilience Score Related Terms

BPTH vs VBIO, HEPA, AXIM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Bio-Path Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Bio-Path Holdings (BPTH) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bio-Path Holdings ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Bio-Path Holdings' Tariff Resilience Score too high?
Bio-Path Holdings' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Bio-Path Holdings' value of 6 is 50% above this industry median. Based on the distribution chart, Bio-Path Holdings ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Bio-Path Holdings' Tariff Resilience Score compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #330 out of 1375 companies for Tariff Resilience Score. This places Bio-Path Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Bio-Path Holdings' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Path Holdings's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.